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VDR and gemini ligands
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The active form of vitamin D, 1α,25-
dihydroxyvitamin D3 [1,25(OH)
2
D3; calcitriol], plays 
a key role in mineral and bone homeostasis, and exerts 
potent anti-inflammatory and anti-proliferative activities 
[1]. It is thus a potential pharmacological agent to treat 
various diseases, including autoimmune disorders, 
infections and cancer [1]. However, the 1,25(OH)
2
D3 
doses required to elicit such effects induce hypercalcemia, 
resulting in ectopic calcification of the vascular wall, 
kidney and other soft tissues, that can lead to organ 
failure and death [1]. 1,25(OH)
2
D3 activities are mediated 
by the Vitamin D receptor (VDR; NR1I1), a member 
of the nuclear receptor superfamily [1]. More than 
3000 VDR ligands were synthesized using medicinal 
chemistry approaches, but all those exhibiting potent anti-
inflammatory and/or anti-proliferative properties still have 
hypercalcemic activities, which limit their clinical use [1]. 
VDR loss-of-function mutations in humans, 
termed Vitamin D-Dependent Rickets type-II (VDDR-
II), and VDR-null mice develop skeletal deformities, 
osteomalacia, hypocalcemia and hypophosphatemia [2]. 
In addition, VDR DNA-binding deficient patients and 
VDR-null mice display alopecia [2]. Hair follicle defects 
in VDR-null mice are prevented by transgenic expression 
of ligand-binding deficient VDR in keratinocytes [3]. 
In contrast, severe deficiencies in 1,25(OH)
2
D3 induced 
by dysfunctional 25(OH)-vitaminD3-1α-hydroxylase 
(Cyp27b1), the enzyme that converts 25(OH)D3 to 
1,25(OH)
2
D3 in VDDR-I patients, as well as in Cyp27b1-
null mice, do not induce alopecia, even though they lead 
to rickets, which can be treated by 1,25(OH)
2
D3 [2, 4]. 
Similarly, patients and mice expressing a mutated VDR 
with reduced affinity for 1,25(OH)
2
D3 without impairing 
DNA binding have skeletal but no hair defects [2]. Thus, 
it appears that liganded VDR is essential for mineral ion 
homeostasis and skeletal metabolism, whereas ligand-
independent VDR activities control hair cycling. 
Phenotypic analyses of mutant mice suggested that 
bone and mineral homeostasis alterations might be more 
pronounced in Cyp27b1-null mice than in VDR-null [4, 
5]. Moreover, data presented in a recent report indicated 
that the size of mice expressing VDRL233S, a VDR bearing 
a mutation in the ligand binding domain that impairs 
calcitriol binding, was reduced compared to VDR-null 
[3]. Taken together, these results indicated that unliganded 
VDR might induce more severe skeletal defects than VDR 
deficiency. 
To characterise VDR ligand-independent activities, 
we generated, based on VDR structural analyses, mice 
expressing a ligand binding domain point-mutated VDR 
(VDRgem) that is unresponsive to 1,25(OH)
2
D3 [6]. 
Phenotypic analyses showed that mineral ion and bone 
homeostasis was more impaired in VDRgem than in 
VDR-null mice, even though they had no hair defects [6]. 
Moreover, selective ablation of VDR in intestinal epithelial 
cells did not affect mineral ion homeostasis [7], while 
selective expression of VDRgem in such cells induced 
hypocalcemia (our unpublished data), thus demonstrating 
that intestinal unliganded VDR strongly impairs calcium 
homeostasis. Importantly, our study revealed that apo-
VDRgem binds to VDR response elements of VDR target 
genes in the mouse duodenum and represses many genes 
[6]. Therefore, the repressive activity of unliganded VDR 
in intestinal epithelial cells accounts, at least in part, for 
increased bone and mineral defects, compared to VDR 
deficiency. 
Alopecia in VDDR-II patients is thought to be 
associated with the severity of rickets and metabolic 
abnormalities [2]. However, as our data show that mice 
expressing ligand-binding deficient VDR develop more 
severe skeletal defects than VDR-null mice, and that only 
the latter have hair defects, it will important to determine 
whether it is also the case in VDDR-II patients, to improve 
the diagnosis and treatment. 
The possibility to restore the transcriptional activity 
of VDR mutants that are unresponsive to natural ligands 
is instrumental to identify VDR target genes. However, 
amongst various VDR agonist tested, none induced 
VDRL233S transcriptional activity (our unpublished data). 
In contrast, we have shown that VDRgem transcriptional 
activity is efficiently induced by gemini ligands, and that 
they restore serum calcium levels of VDRgem mice, 
thus opening new avenues to characterize gene networks 
controlled by VDR ligands in the mouse [6]. Further 
phenotypic and molecular analyses of VDRgem, VDR-
null and wild-type mice treated or not with 1,25(OH)
2
D3 
or gemini ligands should allow to identify the signaling 
pathways controlled by unliganded and liganded VDR in 
various tissues, and thus facilitate the identification of new 
drug targets for various diseases, as well as VDR ligands 
with increased selectivity.
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